Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Current securities

1. SCHEDULE 13G filingAug 31, 2026
2. 10-Q filingAug 5, 2026
3. Results of Operations and Financial ConditionAug 5, 2026
4. Entry into a Material Definitive Agreement · Regulation FD DisclosureAug 4, 2026
5. Entry into a Material Definitive Agreement · Regulation FD DisclosureJul 8, 2026